Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Autodesk Inc (ADSK) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Autodesk IncTrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Autodesk Inc vs Neurocrine Biosciences Inc — how do they compare? Autodesk Inc trades at $248.05 (market cap $54.07B), while Neurocrine Biosciences Inc trades at $154.01 (market cap $16.76B). The key difference: Autodesk Inc is far larger — about 3.2× Neurocrine Biosciences Inc's market cap. Which is the better fit depends on your goals.

ADSKNBIX
Market Cap
$54.07B$16.76B
Sector
TechnologyHealth
52-Week High
$326.79$185.50
52-Week Low
$187.72$123.10
Enterprise Value
$53.87B$16.78B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Autodesk Inc

No Aura AI signal available yet.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.

The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Autodesk Inc

Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.

Read more on ADSK

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX